AKT1 and hepatocellular carcinoma: Yan's research demonstrated the combined use of lenvatinib and SAHA, an HDAC inhibitor, works synergistically to suppress HCC cell proliferation and to trigger cell apoptosis by modulating the PTEN/AKT pathway 102.